Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.870
-0.010 (-0.35%)
At close: Sep 4, 2025, 4:00 PM
2.890
+0.020 (0.70%)
After-hours: Sep 4, 2025, 7:13 PM EDT
BDTX Employees
Black Diamond Therapeutics had 24 employees as of December 31, 2024. The number of employees decreased by 30 or -55.56% compared to the previous year.
Employees
24
Change (1Y)
-30
Growth (1Y)
-55.56%
Revenue / Employee
$2,916,667
Profits / Employee
$601,625
Market Cap
163.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | -30 | -55.56% |
| Dec 31, 2023 | 54 | -11 | -16.92% |
| Dec 31, 2022 | 65 | -21 | -24.42% |
| Dec 31, 2021 | 86 | 17 | 24.64% |
| Dec 31, 2020 | 69 | 37 | 115.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BDTX News
- 10 days ago - Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash - Seeking Alpha
- 4 weeks ago - Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside - Seeking Alpha
- 3 months ago - Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
- 6 months ago - Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy - GlobeNewsWire